US 7,507,537 B2
	Cytotoxicity mediation of cells evidencing surface expression of CD44
David S. F. Young, Toronto (Canada); Susan E. Hahn, Toronto (Canada); and Helen P. Findlay, Toronto (Canada)
Assigned to Hoffmann-La Roche Inc., Nutley, N.J. (US)
Filed on Nov. 03, 2006, as Appl. No. 11/592,516.
Application 11/592516 is a continuation of application No. 10/810165, filed on Mar. 26, 2004, abandoned.
Application 10/810165 is a continuation in part of application No. 10/647818, filed on Aug. 22, 2003, granted, now 7,189,397.
Application 10/647818 is a continuation in part of application No. 10/603000, filed on Jun. 23, 2003, granted, now 7,252,821.
Application 10/603000 is a continuation in part of application No. 09/727361, filed on Nov. 29, 2000, granted, now 6,657,048.
Application 09/727361 is a continuation in part of application No. 09/415278, filed on Oct. 08, 1999, granted, now 6,180,357.
Prior Publication US 2007/0053836 A1, Mar. 08, 2007
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 51/00 (2006.01)

U.S. Cl. 435—6  [424/1.49; 424/155.1]

18 Claims

1. A method of treating a human breast, melanoma or prostate tumor in a mammal, wherein said human tumor expresses at least one epitope of a CD44 antigen which specifically binds to the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC as accession number PTA-4621 or an antigen binding fragment produced from said isolated monoclonal antibody, wherein said antigen binding fragment is characterized by an ability to competitively inhibit binding of said isolated monoclonal antibody to its target antigen, comprising administering to said mammal said monoclonal antibody or said antigen binding fragment in an amount effective to result in a reduction of said mammal's breast, melanoma or prostate tumor burden.